GLG News Analyses of the following article:
Novel BSI-201 Targeted Therapy Holds Promise for Patients with Metastatic Triple-negative Breast Cancer
Published at: www.asco.org
-
PARP Inhibitor shows very encouraging results in metastatic breast cancer
June 3, 2009
PARP inhibitors affect cancer cells by altering their ability to replicate DNA and grow. In theory and in animal models, they work syngergistically with more traditional chemotherapy agents, since PARP inhibition should make chemotherapy (or any drug which damages DNA) more effective. This study was presented at an ASCO plenary session and the reported results are exciting, both for breast cancer and other cancers where these drugs have just begun to be studied.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.